Belinostat and paclitaxel combination reverses bladder cancer chemoresistance by blocking HDAC-p21-senescence axis
Background
Advanced bladder cancer faces significant challenges due to high recurrence rates and the development of chemoresistance, severely limiting treatment options. Current standard-of-care often falls short, necessitating novel therapeutic strategies. Histone deacetylases (HDACs) are epigenetic regulators implicated in tumor progression and drug resistance, yet their precise role in acquired chemoresistance in bladder cancer remains poorly understood. This study investigates whether targeting HDACs can restore chemotherapy sensitivity, addressing a critical gap in overcoming drug-refractory disease.
Study Design
Researchers developed a co-delivery therapeutic strategy combining the pan-HDAC inhibitor belinostat (PXD101) with paclitaxel (PTX). This combination was evaluated in patient-derived cisplatin-resistant organoids and a platinum-refractory patient-derived xenograft (PDX) model. Expression levels of HDAC1-3 were analyzed in bladder cancer tissues and correlated with clinical outcomes and chemoresistance signatures. Functional assays and genetic perturbation experiments were performed to elucidate the underlying mechanisms, focusing on cell-cycle regulation and senescence.
Results
HDAC1-3 were found to be significantly upregulated in bladder cancer tissues, correlating with adverse prognosis and strong chemoresistance signatures.
Combined PXD101 and PTX treatment significantly suppressed tumor growth in both patient-derived organoids and PDX models, demonstrating potent anti-tumor efficacy. Crucially, this combination also showed improved tolerability compared with standard regimens. Mechanistically, PXD101 attenuated senescence-associated programs and reduced
CDKN1A/p21expression, which is a key cell cycle inhibitor. This reduction inp21restoredPTX-induced antimitotic activity, overcoming the resistance mechanism. Genetic manipulation experiments further identifiedp21as a molecular switch, directly linking therapy-induced senescence to the development and maintenance of chemoresistance. Modulation ofp21levels directly influenced cell-cycle re-entry, the burden of senescent cells, and ultimately, responsiveness toPTX.
Key Findings
HDAC1-3were upregulated in bladder cancer tissues, correlating with adverse prognosis and chemoresistance signatures.- Combined belinostat and paclitaxel significantly suppressed tumor growth in patient-derived organoids and PDX models.
- The combination therapy demonstrated improved tolerability compared with standard regimens.
- Belinostat attenuated senescence-associated programs and reduced
CDKN1A/p21expression, restoring paclitaxel's antimitotic activity. p21was identified as a molecular switch linking therapy-induced senescence to chemoresistance.
Why It Matters
A novel therapeutic axis, HDAC-p21-senescence, is defined, offering a promising strategy to overcome acquired chemoresistance in bladder cancer. For clinicians and researchers, this suggests that combining epigenetic modulators like belinostat with antimitotic agents such as paclitaxel could significantly improve outcomes for patients with drug-refractory disease. While currently preclinical, these findings provide strong evidence for advancing this combination therapy towards clinical trials. The identification of p21 as a central molecular switch also opens avenues for biomarker-guided patient selection or the development of targeted p21 modulators to enhance chemosensitivity. This approach could lead to more effective and potentially better-tolerated treatment protocols for a challenging cancer.
bladder-cancer
chemoresistance
belinostat
paclitaxel
hdac-inhibitor
p21